Trial Profile
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 20 Jul 2023 Planned End Date changed from 31 Jul 2024 to 31 Jul 2025.
- 20 Jul 2023 Planned primary completion date changed from 31 Jul 2024 to 31 Jul 2025.
- 20 Jun 2023 Planned End Date changed from 31 Jul 2023 to 31 Jul 2024.